| | Publication Year | Title | Author(s) |
| 1 | 17-Nov-2021 | hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. | Aughton, Karen; Elander, Nils O; Evans, Anthony; Jackson, Richard; Campbell, Fiona; Costello, Eithne; Halloran, Christopher M; Mackey, John R; Scarfe, Andrew G; Valle, Juan W; Carter, Ross; Cunningham, David; Tebbutt, Niall C ; Goldstein, David; Shannon, Jennifer; Glimelius, Bengt; Hackert, Thilo; Charnley, Richard M; Anthoney, Alan; Lerch, Markus M; Mayerle, Julia; Palmer, Daniel H; Büchler, Markus W; Ghaneh, Paula; Neoptolemos, John P; Greenhalf, William |
| 2 | 5-Nov-2021 | Update on optimal management for pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. | Nguyen, Mike ; Segelov, Eva; Goldstein, David; Pavlakis, Nick; Shapiro, Jeremy; Price, Timothy J; Nagrial, Adnan; Chantrill, Lorraine; Leong, Trevor; Chen, John; Burge, Matt; Karapetis, Christos S; Chau, Ian; Lordick, Florian; Renouf, Daniel; Tebbutt, Niall C ; Roy, Amitesh C |
| 3 | 18-Aug-2021 | MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). | Siu, Ho Wai Derrick; Tebbutt, Niall C ; Chantrill, Lorraine; Karapetis, Chris; Steer, Christopher; Wilson, Kate; Espinoza, David; Bailey, Lisa; Yip, Sonia; Cuff, Jeff; Pavlakis, Nick; Thavaneswaran, Subotheni; Briscoe, Karen; Srivastav, Ratnesh; Shannon, Jennifer; Segelov, Eva; Tie, Jeannie; Caird, Susan; Francesconi, Alessandra; Price, Timothy; Wuttke, Melanie; Ladwa, Rahul; Sjoquist, Katrin; Burge, Matthew |
| 4 | 1-Jun-2021 | Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. | Yin, Jun; Cohen, Romain; Jin, Zhaohui; Liu, Heshan; Pederson, Levi; Adams, Richard; Grothey, Axel; Maughan, Timothy S; Venook, Alan; Van Cutsem, Eric; Punt, Cornelis; Koopman, Miriam; Falcone, Alfredo; Tebbutt, Niall C ; Seymour, Matthew T; Bokemeyer, Carsten; Rubio, Eduardo Diaz; Kaplan, Richard; Heinemann, Volker; Chibaudel, Benoist; Yoshino, Takayuki; Zalcberg, John; Andre, Thierry; De Gramont, Aimery; Shi, Qian; Lenz, Heinz-Josef |
| 5 | 3-May-2021 | Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. | Tie, Jeanne; Wang, Yuxuan; Cohen, Joshua; Li, Lu; Hong, Wei; Christie, Michael; Wong, Hui Li; Kosmider, Suzanne; Wong, Rachel; Thomson, Benjamin; Choi, Julian; Fox, Adrian; Field, Kathryn; Burge, Matthew; Shannon, Jenny; Kotasek, Dusan; Tebbutt, Niall C ; Karapetis, Christos; Underhill, Craig; Haydon, Andrew; Schaeffer, Joy; Ptak, Janine; Tomasetti, Cristian; Papadopoulos, Nicholas; Kinzler, Kenneth W; Vogelstein, Bert; Gibbs, Peter |
| 6 | May-2021 | Prevalence of hypoxia and correlation with glycolytic metabolism and angiogenic biomarkers in metastatic colorectal carcinoma. | Lee, Sze Ting ; Muralidharan, Vijayaragavan ; Tebbutt, Niall C ; Wong, P; Fang, C; Liu, Z; Gan, Hui K ; Sachinidis, J; Pathmaraj, Kunthi ; Christophi, Christopher ; Scott, Andrew M |
| 7 | 15-Apr-2021 | Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study. | Mooi, Jennifer K ; Chionh, Fiona; Savas, Peter; Da Gama Duarte, Jessica; Chong, Geoffrey ; Brown, Stephen; Wong, Rachel; Price, Timothy J; Wann, Alysson ; Skrinos, Effie; Mariadason, John M ; Tebbutt, Niall C |
| 8 | 17-Mar-2021 | Evaluation of 18F-FMISO PET and 18F-FDG PET Scans in Assessing the Therapeutic Response of Patients With Metastatic Colorectal Cancer Treated With Anti-Angiogenic Therapy. | Lee, Sze Ting ; Tebbutt, Niall C ; Gan, Hui K ; Liu, Zhanqi; Sachinidis, John; Pathmaraj, Kunthi ; Scott, Andrew M |
| 9 | 22-Feb-2021 | Rapid resistance of FGFR-driven gastric cancers to regorafenib and targeted FGFR inhibitors can be overcome by parallel inhibition of MEK. | Lau, David K ; Luk, Ian Y; Jenkins, Laura J; Martin, Andrew; Williams, David S ; Schoffer, Kael L; Chionh, Fiona; Buchert, Michael; Sjoquist, Katrin; Boussioutas, Alex; Hayes, Sarah A; Ernst, Matthias ; Weickhardt, Andrew J ; Pavlakis, Nick; Tebbutt, Niall C ; Mariadason, John M |
| 10 | 15-Feb-2021 | Prognostic Significance of Post-Surgery Circulating Tumor DNA in Non-Metastatic Colorectal Cancer: Individual Patient Pooled Analysis of Three Cohort Studies. | Tie, Jeanne; Cohen, Joshua D; Lo, Serigne N; Wang, Yuxuan; Li, Lu; Christie, Michael; Lee, Margaret; Wong, Rachel; Kosmider, Suzanne; Skinner, Iain; Wong, Hui Li; Lee, Belinda; Burge, Matthew E; Yip, Desmond; Karapetis, Christos S; Price, Timothy J; Tebbutt, Niall C ; Haydon, Andrew M; Ptak, Janine; Schaeffer, Mary J; Silliman, Natalie; Dobbyn, Lisa; Popoli, Maria; Tomasetti, Cristian; Papadopoulos, Nickolas; Kinzler, Kenneth W; Vogelstein, Bert; Gibbs, Peter |
| 11 | 29-Jan-2021 | Dual anti-angiogenesis agents bevacizumab plus trebananib, without chemotherapy, in first-line treatment of metastatic colorectal cancer: results of a phase II study. | Mooi, Jennifer K ; Chionh, Fiona; Savas, Peter; Da Gama Duarte, Jessica; Chong, Geoffrey ; Brown, Stephen; Wong, Rachel; Price, Timothy; Wann, Alysson ; Skrinos, Effie; Mariadason, John M ; Tebbutt, Niall C |
| 12 | 1-Jan-2021 | Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. | Schmoll, Hans-Joachim; Stein, Alexander; Van Cutsem, Eric; Price, Timothy; Hofheinz, Ralf D; Nordlinger, Bernard; Daisne, Jean-François; Janssens, Jos; Brenner, Baruch; Reinel, Hans; Hollerbach, Stephan; Caca, Karel; Fauth, Florian; Hannig, Carla V; Zalcberg, John; Tebbutt, Niall C ; Mauer, Murielle E; Marreaud, Sandrine; Lutz, Manfred P; Haustermans, Karin |
| 13 | 2021 | Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group. | Dunn, Catherine; Hong, Wei; Gibbs, Peter; Ackland, Stephen; Sjoquist, Katrin; Tebbutt, Niall C ; Price, Timothy; Burge, Matthew |
| 14 | 1-Nov-2020 | Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA. | Gulhati, Pat; Yin, Jun; Pederson, Levi; Schmoll, Hans-Joachim; Hoff, Paulo; Douillard, Jean-Yves; Hecht, J Randolph; Tournigand, Christophe; Tebbutt, Niall C ; Chibaudel, Benoist; Gramont, Aimery De; Shi, Qian; Overman, Michael James |
| 15 | 1-Sep-2020 | Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial. | Klein, Oliver ; Kee, Damien ; Nagrial, Adnan; Markman, Ben; Underhill, Craig; Michael, Michael; Jackett, Louise A ; Lum, Caroline; Behren, Andreas; Palmer, Jodie ; Tebbutt, Niall C ; Carlino, Matteo S; Cebon, Jonathan S |
| 16 | 20-Apr-2020 | Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. | Roy, Amitesh C; Shapiro, Jeremy; Burge, Matt; Karapetis, Christos S; Pavlakis, Nick; Segelov, Eva; Chau, Ian; Lordick, Florian; Chen, Li-Tong; Barbour, Andrew; Tebbutt, Niall C ; Price, Tim |
| 17 | Apr-2020 | Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO Congress 2019. | Lau, David K ; Burge, Matthew; Roy, Amitesh; Chau, Ian; Haller, Daniel G; Shapiro, Jeremy D; Peeters, Marc; Pavlakis, Nick; Karapetis, Christos S; Tebbutt, Niall C ; Segelov, Eva; Price, Timothy J |
| 18 | 19-Mar-2020 | Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients with Elevated CEA. | Gulhati, Pat; Yin, Jun; Pederson, Levi; Schmoll, Hans-Joachim; Hoff, Paulo; Douillard, Jean-Yves; Hecht, J Randolph; Tournigand, Christophe; Tebbutt, Niall C ; Chibaudel, Benoist; De Gramont, Aimery; Shi, Qian; Overman, Michael James |
| 19 | Mar-2020 | Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer. | Williams, David S ; Mouradov, Dmitri; Browne, Clare; Palmieri, Michelle; Elliott, Meg J; Nightingale, Rebecca; Fang, Catherine G; Li, Rita; Mariadason, John M ; Faragher, Ian; Jones, Ian T; Churilov, Leonid ; Tebbutt, Niall C ; Gibbs, Peter; Sieber, Oliver M |
| 20 | 2020 | The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]. | Clarke, Stephen John; Burge, Matthew; Feeney, Kynan; Gibbs, Peter; Jones, Kristian; Marx, Gavin; Molloy, Mark P; Price, Timothy; Reece, William H H; Segelov, Eva; Tebbutt, Niall C |